Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysisMaryam Movassaghian, Amir T. Fathi, Andrew M. Brunner et al.|Leukemia & lymphoma/Leukemia and lymphoma|2014Cited by 95
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemiaAmir T. Fathi, Yi‐Bin Chen, Amity L. Manning et al.|Haematologica|2016Cited by 43
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutationAmir T. Fathi, Mark J. Levis, Traci M. Blonquist et al.|Cancer|2017Cited by 31
Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: A SEER database analysisAndrew M. Brunner, Amir T. Fathi, Traci M. Blonquist et al.|Leukemia Research|2014Cited by 30
The End of Life for Patients with Acute Myeloid Leukemia (AML)- a Single Center ExperienceJudy Foster, Karen K. Ballen, Traci M. Blonquist et al.|Blood|2015Cited by 4